Walleye Capital
GSK icon

Walleye Capital’s GSK GSK Stock Holding History

Walleye Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Buy
402,472
+29,376
+8% +$1.55M 0.08% 237
2026
Q1 		$20.6M Buy
373,096
+321,192
+619% +$17.4M 0.09% 187
2025
Q4 		$2.55M Sell
51,904
-121,973
-70% -$5.69M 0.01% 1680
2025
Q3 		$7.5M Buy
173,877
+136,659
+367% +$5.34M 0.03% 683
2025
Q2 		$1.43M Buy
37,218
+16,447
+79% +$628K 0.01% 1767
2025
Q1 		$805K Sell
20,771
-7,199
-26% -$264K ﹤0.01% 2156
2024
Q4 		$946K Buy
27,970
+18,696
+202% +$673K ﹤0.01% 2433
2024
Q3 		$379K Sell
9,274
-192,298
-95% -$7.87M ﹤0.01% 3548
2024
Q2 		$7.76M Buy
201,572
+199,629
+10,274% +$8.4M 0.01% 935
2024
Q1 		$83.3K Sell
1,943
-18,274
-90% -$754K ﹤0.01% 4486
2023
Q4 		$749K Buy
+20,217
New +$726K ﹤0.01% 2620
2018
Q3 		$1.21M Buy
+23,994
New +$1.22M 0.56% 49

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Walleye Capital's GSK Position: Q2 2026 in Review

Walleye Capital increased its GSK (GSK) stake by 7.9% in Q2 2026, buying an estimated $1.55M and bringing the position to 402,472 shares worth $21.1M. The position accounts for 0.08% of the portfolio, ranked #237.

Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 12 quarters since. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Walleye Capital held 402,472 shares of GSK worth $21.1M as of Q2 2026.
  • Walleye Capital bought 29,376 GSK shares in Q2 2026, an estimated $1.55M.
  • GSK made up 0.08% of Walleye Capital's portfolio in Q2 2026, its #237 holding.
  • Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 12 quarters since.
  • 1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.